Facial nerve paralysis after super-selective intra-arterial chemotherapy for oral cancer. Issue 6 (June 2017)

• Record Type: Journal Article
• Authors: Sugiyama, S.; Iwai, T.; Oguri, S.; Koizumi, T.; Mitsudo, K.; Tohnai, I.
• Is Part Of: International journal of oral & maxillofacial surgery. Volume 46:Issue 6(2017:Jun.)
• Page Start: 682
• Page End: 686
• Publication Date: 2017-06
• Subjects: facial nerve paralysis -- intra-arterial chemotherapy -- super-selective intra-arterial chemotherapy -- oral cancer -- complication; Mouth -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Dentistry -- Periodicals; Dentistry, Operative; Oral Surgical Procedures; Surgery, Oral; Dentistry; Maxilla -- Surgery; Mouth -- Surgery; Electronic journals; Periodicals; 617.52059
• DOI: 10.1016/j.ijom.2017.01.011
• Languages: English
• ISSNs: 0901-5027

Abstract

Abstract: Facial nerve paralysis (FNP) after super-selective intra-arterial chemotherapy (SSIAC) is a relatively rare local side effect of SSIAC to the maxillary artery (MA) or the middle meningeal artery (MMA). The incidence and prognosis of FNP after SSIAC in 381 patients with oral cancer (133 with catheterization of the MA, 248 without) was investigated retrospectively. Only three patients (two male and one female) had FNP, for an incidence of 0.8%. All patients with FNP had undergone catheterization of the MA, and the incidence of FNP in this group was 2.3% (3/133). One of the three patients with FNP had paralysis of the third branch of the trigeminal nerve. FNP occurred a mean of 8.7 days (range 5–11 days) after initial SSIAC, and the mean total dose of cisplatin was 55.8 mg (range 42.5–67.2 mg) and of docetaxel was 25.4 mg (range 17.0–33.6 mg). FNP resolved completely a mean of 12.7 months (range 6–19 months) after onset. Because the administration of anticancer agents via the MA or MMA carries a risk of FNP, this information will be useful when obtaining informed consent from patients before treatment.